ChoA Pharmaceutical Co., LTD. Logo

ChoA Pharmaceutical Co., LTD.

Global manufacturer of OTC medicines and health supplements distributed through pharmacies.

034940 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
서울특별시 영등포구 당산로2길 12 에이스테크노타워 101호(문래동3가, 에이스테크노타워1층), 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Established in 1988, ChoA Pharmaceutical Co., LTD. develops, manufactures, and supplies a range of pharmaceutical products and health foods. The company's portfolio includes approximately 200 products, specializing in over-the-counter (OTC) medicines, health supplements, digestives, and nutritional tonics. ChoA Pharmaceutical is recognized for its various product formulations, including tablets, capsules, liquids, and a significant line of drinkable ampoule products. The company focuses on pharmacies as its primary distribution channel and maintains a global business presence, exporting its products to various regions in Asia, the Middle East, and the Americas.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.2 MB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.0 MB
2025-03-24 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 22.3 KB
2025-03-14 00:00
Audit Report / Information
감사보고서제출
Korean 25.8 KB
2025-03-14 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 586.6 KB
2025-02-28 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 137.2 KB
2025-02-28 00:00
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
Korean 139.1 KB
2025-02-21 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 11.1 KB
2025-02-21 00:00
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 11.3 KB
2025-02-03 00:00
Regulatory News Service
생산재개(자율공시)
Korean 7.8 KB

Automate Your Workflow. Get a real-time feed of all ChoA Pharmaceutical Co., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for ChoA Pharmaceutical Co., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.